Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

132 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
DNA topoisomerases as targets for the anticancer drug TAS-103: primary cellular target and DNA cleavage enhancement.
Byl JA, Fortune JM, Burden DA, Nitiss JL, Utsugi T, Yamada Y, Osheroff N. Byl JA, et al. Among authors: utsugi t. Biochemistry. 1999 Nov 23;38(47):15573-9. doi: 10.1021/bi991791o. Biochemistry. 1999. PMID: 10569941
TAS-103 is a novel antineoplastic agent that is active against in vivo tumor models [Utsugi, T., et al. (1997) Jpn. J. Cancer Res. 88, 992-1002]. This drug is believed to be a dual topoisomerase I/II-targeted agent, because it enhances both topoisomerase I- and topo …
TAS-103 is a novel antineoplastic agent that is active against in vivo tumor models [Utsugi, T., et al. (1997) Jpn. J. Cancer …
DNA topoisomerases as targets for the anticancer drug TAS-103: DNA interactions and topoisomerase catalytic inhibition.
Fortune JM, Velea L, Graves DE, Utsugi T, Yamada Y, Osheroff N. Fortune JM, et al. Among authors: utsugi t. Biochemistry. 1999 Nov 23;38(47):15580-6. doi: 10.1021/bi991792g. Biochemistry. 1999. PMID: 10569942
TAS-103 is unusual in that it reportedly inhibits the catalytic activity of both topoisomerase I and II and does so at physiologically relevant concentrations [Utsugi, T., et al. (1997) Jpn. J. Cancer Res. 88, 992-1002]. Without a topoisomerase activity to relieve a …
TAS-103 is unusual in that it reportedly inhibits the catalytic activity of both topoisomerase I and II and does so at physiologically relev …
DNA topoisomerase II as the target for the anticancer drug TOP-53: mechanistic basis for drug action.
Byl JA, Cline SD, Utsugi T, Kobunai T, Yamada Y, Osheroff N. Byl JA, et al. Among authors: utsugi t. Biochemistry. 2001 Jan 23;40(3):712-8. doi: 10.1021/bi0021838. Biochemistry. 2001. PMID: 11170388
TOP-53 is a promising anticancer agent that displays high activity against non-small cell lung cancer in animal tumor models [Utsugi, T., et al. (1996) Cancer Res. 56, 2809-2814]. Compared to its parent compound, etoposide, TOP-53 is considerably more toxic to non-s …
TOP-53 is a promising anticancer agent that displays high activity against non-small cell lung cancer in animal tumor models [Utsugi, …
132 results